公司資料
Natera 股價、新聞與催化劑
- 股票代碼:
- NTRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
366.31 USD (+6.07%)
收盤價
最後更新: 2026年9月17日
30.5B USD
市值
股價為何變動
截至 2026年9月17日，NTRA 上漲 6.07%，收於 $366.31。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Natera is a molecular diagnostics company focused on cell-free DNA testing across oncology, women's health, and organ health.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Natera sits in precision diagnostics rather than therapeutics.
商業模式特徵
The business is driven by test volume, reimbursement, and the expansion of its oncology and reproductive-testing franchises.
生技產業定位
Natera occupies a top-tier diagnostics niche because its platform can scale across multiple clinical use cases.
未來催化劑
- Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。